NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: BASF

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BASF Pharma Solutions Introduces 'VPA Premium Services' to its Virtual Pharma Assistants (VPAs) Digital Services Platform - BASF Pharma Solutions expands its Virtual Pharma Assistants (VPA) platform by launching “VPA Premium Services”, a selection of new service options developed to meet customer demands for expanded access and content within the platforms - BASF.com
BASF Pharma Solutions Introduces 'VPA Premium Services' to its Virtual Pharma Assistants (VPAs) Digital Services Platform

 

NewswireTODAY - /newswire/ - Florham Park, NJ, United States, 2023/10/23 - BASF Pharma Solutions expands its Virtual Pharma Assistants (VPA) platform by launching “VPA Premium Services”, a selection of new service options developed to meet customer demands for expanded access and content within the platforms - BASF.com. Frankfurt (BAS)

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• VPA Premium Services offers users the option to purchase access to new exclusive features within the VPAs;
• “Corporate Premium”, the first premium service introduced, allows drug formulators to confidentially share and collaborate on projects under a single Corporate Account, and unlocks access to premium content, scientific support and training;
• Additional premium services in RegXcellence® will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports.

The Virtual Pharma Assistants (VPAs) (virtualpharmaassistants.basf.com) were originally developed by BASF Pharma Solutions as a way for customers to accelerate formulation design by predicting the most effective excipients given the properties of an active pharmaceutical ingredient, and to easily access quality and regulatory documents for BASF products. These self-services are free of charge and currently widely used and highly valued by our customers.

The first VPA Premium Service available in ZoomLab™,“Corporate Premium”, allows formulators within the same organization to be grouped under one “Corporate Account” where they can confidentially share and collaborate on projects. In addition,“Corporate Premium” unlocks access to further premium content, scientific support, and exclusive training materials.

Future VPA Premium Services launched within RegXcellence® will allow users immediate access to BASF’s Product Carbon Footprint data and the ability to directly download audit reports.

“The Virtual Pharma Assistants are key in providing digital services for our customers. With the addition of premium services to our portfolio, we are meeting the growing demands of our customers for specific service requests. Premium features will grant them instant access to key insights and collaboration platforms they need for their work in a quick and efficient manner via our digital service platform,” states Marion Kuhn, Vice President, Global Business Management, Pharma Solutions.

“Corporate Premium” is our solution for customers who want their Formulators & Scientists to collaboratively work on drug formulation projects with ZoomLab™. They will benefit from advanced data privacy and project administration features tailored to their needs. Also, direct access to BASF formulation experts will allow them to get to solutions faster,” states Rainer Dobrawa, Global Head of Marketing, Pharma Solutions.

About BASF

At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 111,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €87.3 billion in 2022.

About BASF’s Nutrition & Health division

BASF Nutrition & Health (basf.com) provides a comprehensive product and service range for human and animal nutrition, pharmaceutical, and flavor & fragrance industries. With our science-driven portfolio, we address customers in globally growing markets to meet the demands of an expanding world population. Together with our customers, we play an active role in enhancing the nutrition, health and wellbeing of consumers all over the world. Our products fulfill the highest safety, regulatory and sustainability standards. BASF Nutrition & Health operates sites in Europe, North America and in Asia-Pacific.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: BASF

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BASF Pharma Solutions Introduces 'VPA Premium Services' to its Virtual Pharma Assistants (VPAs) Digital Services Platform

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
VPA Premium Services | BASF’s Nutrition & Health
Contact: John Bell - BASF.com 
848 200-8874 john.bell[.]basf.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BASF securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BASF / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases
OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer
Ipsen Completes Acquisition of Memo Therapeutics AG, Adding First-in-class Asset to Ipsen’s Rare Disease Pipeline
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit BizJobs.com





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)